Aguni

Researchers are evaluating the safety and effectiveness of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease (PAD), a condition causing pain and difficulty walking due to narrowed arteries. This Phase 3 randomized, double-blind, placebo-controlled trial aims to understand how orforglipron affects walking ability and overall safety in people with this condition. Participants will be involved in the study for about 58 weeks. Participants will receive either orforglipron or a placebo, both administered orally once daily. The study includes a comparison between these two groups to assess the impact of orforglipron on walking distance and other health outcomes over the course of the trial. During the study, researchers will measure changes in the maximum distance participants can walk compared to their baseline, particularly at the start and after 52 weeks of treatment. Participants will be monitored for safety and any side effects throughout the study. The total duration of participation is approximately 58 weeks, allowing for thorough evaluation of the treatment's effects and safety.

Researchers are evaluating the effects of oral ivosidenib in adults with locally advanced or metastatic conventional chondrosarcoma that has an IDH1 gene mutation. This Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study includes participants with Grades 1, 2, or 3 chondrosarcoma who are not eligible for curative surgery and have experienced disease progression or recurrence. The study focuses on participants who have received zero or one prior systemic treatment in the advanced or metastatic setting. The main goal is to measure progression-free survival in participants with Grade 1 and 2 tumors. Participants who qualify will be randomly assigned in a 1:1 ratio to receive either oral ivosidenib 500 mg once daily, given as two 250 mg tablets, or a matching placebo once daily. The treatment period will continue until disease progression or unacceptable side effects occur. The study assesses the therapy's impact on disease control compared to placebo in this patient population. During the study, participants will undergo regular imaging assessments to track tumor size and progression according to standardized criteria. IDH1 mutation status is confirmed centrally before enrollment. Researchers will monitor progression-free survival as the primary outcome and also evaluate overall survival. Safety and recovery from prior treatments will be closely observed throughout the trial, which may last up to approximately 31 months for the main outcome assessment.